🇺🇸 FDA
Patent

US 12133840

Halogenated xanthene composition and method for treating hematologic cancers

granted A61KA61K31/21A61K31/352

Quick answer

US patent 12133840 (Halogenated xanthene composition and method for treating hematologic cancers) held by Provectus Pharmatech, Inc. expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Provectus Pharmatech, Inc.
Grant date
Tue Nov 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K31/21, A61K31/352, A61K31/365, A61K9/0019